Loading, please wait ...

News Analytics

Alvotech signs supply agreement with Fuji Pharma.
The deal means that Alvotech will receive an upfront fee of $4.6m (€4m) and could receive an additional $20m in milestone payments. In return, Fuji Pharma will have exclusive rights to commercialise Alvotech’s ustekinumab biosimilar, which could enter the Japanese market as a competitor to Johnson & Johnson’s Stelara.

The Angle

Subject Matter

  • Business, economics, society 100.00%
    • Companies, industries, organizations 74.65%
    • Society and people 25.35%

Emotional Reaction






Dimensions/Depth Chart

If you find a dimension intereseting, we recommend you pick up one or two facts that you find intriguing and place them into your memory. That way you will have 2nd degree information about the topic if it comes up in conversation.

Accordingly, you can do the same with others as well.